Precision therapies targeting
treatment-resistant cancer.
Innovative Cancer Diagnostic and Treatment Solutions
At PAN Biologics, we are pioneering advanced diagnostic and therapeutic radiopharmaceuticals that target cancer with precision.
About PAN Biologics
Innovating Cancer Treatment Solutions
PAN Biologics is a spinout from Oak Ridge National Laboratory focused on developing first-in-class radiopharmaceuticals and biologics that target key signaling pathways driving cancer progression. With proprietary technologies and advanced protein engineering, we are building a dual-action platform that blocks tumor signaling at its source and delivers precision therapies like Actinium-225. Our innovations aim to transform outcomes in difficult-to-treat cancers.
Our Technology
Diagnostic and Therapy
Innovative radiopharmaceuticals targeting cancer with precision and efficacy.
Radiotherapeutics
Selective Inhibition. Precision Delivery.
- Custom-engineered peptides block HGF/c-MET signaling.
- Payload: Actinium-225 for alpha-particle therapy.
- Efficacy in tumors resistant to current modalities.
Liquid Biopsy Diagnostics
Functional ctDNA Detection from Plasma
- Engineered HGF variants detect active c-MET in patient blood.
- Real-time monitoring of tumor signaling dynamics.
- Clinically actionable, minimally invasive.
Mechanism-Based Drug Screening
Accelerating Oncology Drug Development
- Validates therapeutic impact on c-MET pathway.
- Functional, phenotypic, and receptor-level assays.
- Ideal for pharma & biotech partnerships.
Our Team
PAN Biologics was founded by Dr. Kuntal De, a scientist with a stellar research background from the Cleveland Clinic, The Ohio State University’s James Cancer Hospital, and Oak Ridge National Laboratory. Dr. De launched PAN Biologics to bring cutting-edge science out of the lab and into the clinic, focusing on precision therapies for resistant cancers. Our team brings deep expertise in oncology, molecular biology, and radiopharmaceutical development, combining academic excellence with a passion for real-world impact.
News & Publication
Science-Driven. Patient-Focuse
A. “Basic to Breakthrough” research article by DOE (Department of Energy) Office of Science.
C. How plant biology research could inform COVID-19 treatments.
B. Research was selected as one of the top 10 News highlights in the whole academic year 2022 and 2023 from ORNL (Nation’s largest multidisciplinary science program).
D. Government Media Spotlight: The Science Behind PAN Biologics”